Basic Information
RNALocate ID: | RLID:11000720 |
RNA Symbol: | hsa-miR-19a-3p |
Localization: | Extracellular vesicle |
RNA Information
RNA Name: | hsa-miR-19a |
RNA ID: | miRBase:MIMAT0000073 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22849433 |
Tissue/Cell Line: | HEK-293T cells |
Method: | Next-generation RNA sequencing |
Description: | The total numbers of reads >15 bp matching each miRNA were calculated. These values were then normalized to number of reads per million mapped (RPMM) in each library, to enable direct comparison of expression levels. As a measure of the relative levels of expression of individual miRNAs in cells and EVs, the log (base two) of the ratio of the read number in EVs over that in cells was calculated (log2 (EV/cell)). The miRNA expression data for cells and EVs is presented in Additional file 1: Table S1. Data are collected from Table S1. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001278 | Cytoplasm | Colon cancer cells | 20864815 |
RLID:01001279 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001280 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001281 | Nucleolus | Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001282 | Nucleus | Neural progenitor cells | 21363885 |
RLID:11000710 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000711 | Exosome | Renal cancer cells | 21670082 |
RLID:11000712 | Exosome | Breast milk | 22211110 |
RLID:11000713 | Exosome | Brain tissue | 23382797 |
RLID:11000714 | Exosome | Plasma | 23663360 |
RLID:11000715 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000716 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
RLID:11000717 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11000718 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000719 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
RLID:11000721 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000722 | Microvesicle | Follicular fluid | 23666971 |
RLID:11000723 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000010 | Exosome | B lymphoblastoid cells|Colon tissue|Endothelial cells|Lymphoma tissue | |
RLID-D:11000272 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-19a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-25274 |
MNDR | hsa-miR-19a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-25275 |
MNDR | hsa-miR-19a-3p | Oral squamous cell carcinoma | MNDR-E-MI-25276 |
MNDR | hsa-miR-19a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-25277 |
MNDR | hsa-miR-19a-3p | Follicular cleaved lymphoma | MNDR-E-MI-25278 |
MNDR | hsa-miR-19a-3p | Medulloblastoma | MNDR-E-MI-25279 |
MNDR | hsa-miR-19a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25280 |
MNDR | hsa-miR-19a-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-25281 |
MNDR | hsa-miR-19a-3p | Autism spectrum disorder | MNDR-E-MI-25282 |
MNDR | hsa-miR-19a-3p | Lymphoma | MNDR-E-MI-25283 |
MNDR | hsa-miR-19a-3p | Lymphoma non-hodgkin | MNDR-E-MI-25284 |
MNDR | hsa-miR-19a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-25285 |
MNDR | hsa-miR-19a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-25286 |
MNDR | hsa-miR-19a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-25287 |
MNDR | hsa-miR-19a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-25288 |
MNDR | hsa-miR-19a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-25289 |
MNDR | hsa-miR-19a-3p | Breast cancer luminal | MNDR-E-MI-25290 |
MNDR | hsa-miR-19a-3p | Niemann-pick disease type c | MNDR-E-MI-25291 |
MNDR | hsa-miR-19a-3p | Lymphoblastic lymphoma | MNDR-E-MI-25292 |
MNDR | hsa-miR-19a-3p | Thyroid carcinoma anaplastic | MNDR-E-MI-25293 |
MNDR | hsa-miR-19a-3p | Prostate cancer | MNDR-E-MI-25294 |
MNDR | hsa-miR-19a-3p | Gastric cancer | MNDR-E-MI-25295 |
MNDR | hsa-miR-19a-3p | Gastric lymphoma | MNDR-E-MI-25296 |
MNDR | hsa-miR-19a-3p | Alzheimer disease | MNDR-E-MI-25297 |
MNDR | hsa-miR-19a-3p | Intracranial aneurysm | MNDR-E-MI-25298 |
MNDR | hsa-miR-19a-3p | Bladder cancer | MNDR-E-MI-25299 |
MNDR | hsa-miR-19a-3p | Esophageal carcinoma | MNDR-E-MI-25300 |
MNDR | hsa-miR-19a-3p | Dysautonomia familial | MNDR-E-MI-25301 |
MNDR | hsa-miR-19a-3p | Head and neck cancer | MNDR-E-MI-25302 |
MNDR | hsa-miR-19a-3p | Leukemia | MNDR-E-MI-25303 |
MNDR | hsa-miR-19a-3p | Huntington disease | MNDR-E-MI-25304 |
MNDR | hsa-miR-19a-3p | Cardiovascular disease | MNDR-E-MI-25305 |
MNDR | hsa-miR-19a-3p | Moyamoya disease | MNDR-E-MI-25306 |
MNDR | hsa-miR-19a-3p | Lung cancer | MNDR-E-MI-25307 |
MNDR | hsa-miR-19a-3p | Parkinson disease | MNDR-E-MI-25308 |
MNDR | hsa-miR-19a-3p | Machado-joseph disease | MNDR-E-MI-25309 |
MNDR | hsa-miR-19a-3p | Niemann-pick disease | MNDR-E-MI-25310 |
MNDR | hsa-miR-19a-3p | Basal-like breast cancer | MNDR-E-MI-25311 |
MNDR | hsa-miR-19a-3p | Congenital heart disease | MNDR-E-MI-25312 |
MNDR | hsa-miR-19a-3p | Neuroendocrine neoplasia | MNDR-E-MI-25313 |
MNDR | hsa-miR-19a-3p | Pancreatic cancer | MNDR-E-MI-25314 |
MNDR | hsa-miR-19a-3p | Melanoma | MNDR-E-MI-25315 |
MNDR | hsa-miR-19a-3p | Rectum adenocarcinoma | MNDR-E-MI-25316 |
MNDR | hsa-miR-19a-3p | Nephroblastoma | MNDR-E-MI-25317 |
MNDR | hsa-miR-19a-3p | Colon cancer | MNDR-E-MI-25318 |
MNDR | hsa-miR-19a-3p | Colon adenocarcinoma | MNDR-E-MI-25319 |
MNDR | hsa-miR-19a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-25320 |
MNDR | hsa-miR-19a-3p | Familial ovarian cancer | MNDR-E-MI-25321 |
MNDR | hsa-miR-19a-3p | Prostate adenocarcinoma | MNDR-E-MI-25322 |
MNDR | hsa-miR-19a-3p | Thyroid adenomas | MNDR-E-MI-25323 |
MNDR | hsa-miR-19a-3p | Carcinoma ductal breast | MNDR-E-MI-25324 |
MNDR | hsa-miR-19a-3p | Glioblastoma | MNDR-E-MI-25325 |
MNDR | hsa-miR-19a-3p | Astrocytoma | MNDR-E-MI-25326 |
MNDR | hsa-miR-19a-3p | Glioma | MNDR-E-MI-25327 |
MNDR | hsa-miR-19a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-25328 |
MNDR | hsa-miR-19a-3p | Osteosarcoma | MNDR-E-MI-25329 |
MNDR | hsa-miR-19a-3p | Liposarcoma | MNDR-E-MI-25330 |
MNDR | hsa-miR-19a-3p | Cervical adenocarcinoma | MNDR-E-MI-25331 |
MNDR | hsa-miR-19a-3p | Gastric adenocarcinoma | MNDR-E-MI-25332 |
MNDR | hsa-miR-19a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-25333 |
MNDR | hsa-miR-19a-3p | Lung squamous cell carcinoma | MNDR-E-MI-25334 |
MNDR | hsa-miR-19a-3p | Lung adenocarcinoma | MNDR-E-MI-25335 |
MNDR | hsa-miR-19a-3p | Adrenocortical cancer | MNDR-E-MI-25336 |
MNDR | hsa-miR-19a-3p | Thyroid carcinoma | MNDR-E-MI-25337 |
MNDR | hsa-miR-19a-3p | Bladder urothelial carcinoma | MNDR-E-MI-25338 |
MNDR | hsa-miR-19a-3p | Carcinoma renal cell | MNDR-E-MI-25339 |
MNDR | hsa-miR-19a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25340 |
MNDR | hsa-miR-19a-3p | Renal clear cell carcinoma | MNDR-E-MI-25341 |
MNDR | hsa-miR-19a-3p | Cholangiocarcinoma | MNDR-E-MI-25342 |
MNDR | hsa-miR-19a-3p | Esophageal cancer | MNDR-E-MI-25343 |
MNDR | hsa-miR-19a-3p | Lung small cell carcinoma | MNDR-E-MI-25344 |
MNDR | hsa-miR-19a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-25345 |
MNDR | hsa-miR-19a-3p | Notch-induced t-cell acute lymphoblastic leukemia | MNDR-E-MI-25346 |
MNDR | hsa-miR-19a-3p | Cowden disease | MNDR-E-MI-25347 |
MNDR | hsa-miR-19a-3p | Breast invasive carcinoma | MNDR-E-MI-25348 |
MNDR | hsa-miR-19a-3p | Hepatocellular carcinoma | MNDR-E-MI-25349 |
MNDR | hsa-miR-19a-3p | Familiar ovarian carcinoma | MNDR-E-MI-25350 |
MNDR | hsa-miR-19a-3p | B-cell lymphoma | MNDR-E-MI-25351 |
MNDR | hsa-miR-19a-3p | Rheumatoid arthritis | MNDR-E-MI-25352 |
MNDR | hsa-miR-19a-3p | T-cell leukemia | MNDR-E-MI-25353 |
MNDR | hsa-miR-19a-3p | Malignant pleural mesothelioma | MNDR-E-MI-25354 |
MNDR | hsa-miR-19a-3p | Cervical carcinoma | MNDR-E-MI-25355 |
MNDR | hsa-miR-19a-3p | Retinoblastoma | MNDR-E-MI-25356 |
MNDR | hsa-miR-19a-3p | Neuroblastoma | MNDR-E-MI-25357 |
MNDR | hsa-miR-19a-3p | Barrett's adenocarcinoma | MNDR-E-MI-25358 |
MNDR | hsa-miR-19a-3p | Hodgkin lymphoma | MNDR-E-MI-25359 |
MNDR | hsa-miR-19a-3p | Ulcerative colitis | MNDR-E-MI-25360 |
MNDR | hsa-miR-19a-3p | Burkitt lymphoma | MNDR-E-MI-25361 |
MNDR | hsa-miR-19a-3p | Lymphosarcoma | MNDR-E-MI-25362 |
MNDR | hsa-miR-19a-3p | Crohn disease | MNDR-E-MI-25363 |
MNDR | hsa-miR-19a-3p | Tonsil cancer | MNDR-E-MI-25364 |
MNDR | hsa-miR-19a-3p | Psoriasis | MNDR-E-MI-25365 |
MNDR | hsa-miR-19a-3p | Acute myelogenous leukemia | MNDR-E-MI-25366 |
MNDR | hsa-miR-19a-3p | Colorectal cancer | MNDR-E-MI-25367 |
MNDR | hsa-miR-19a-3p | Nasopharynx carcinoma | MNDR-E-MI-25368 |
MNDR | hsa-miR-19a-3p | Acute myocardial infarction | MNDR-E-MI-25369 |
MNDR | hsa-miR-19a-3p | Multiple myeloma | MNDR-E-MI-25370 |
MNDR | hsa-miR-19a-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-25371 |
MNDR | hsa-miR-19a-3p | Ependymoma | MNDR-E-MI-25372 |
MNDR | hsa-miR-19a-3p | Nasopharyngeal cancer | MNDR-E-MI-25373 |
MNDR | hsa-miR-19a-3p | Prostatic neoplasms | MNDR-E-MI-25374 |
MNDR | hsa-miR-19a-3p | Pseudorabies | MNDR-E-MI-25375 |
MNDR | hsa-miR-19a-3p | Aids dementia complex | MNDR-E-MI-25376 |
MNDR | hsa-miR-19a-3p | Epstein-barr virus infections | MNDR-E-MI-25377 |
MNDR | hsa-miR-19a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-25378 |
MNDR | hsa-miR-19a-3p | Arsenic poisoning | MNDR-E-MI-25379 |
MNDR | hsa-miR-19a-3p | Chronic pain | MNDR-E-MI-25380 |
MNDR | hsa-miR-19a-3p | Stroke lacunar | MNDR-E-MI-25381 |
MNDR | hsa-miR-19a-3p | Barrett's carcinogenesis | MNDR-E-MI-25382 |
MNDR | hsa-miR-19a-3p | Breast cancer her3+ negative | MNDR-E-MI-25383 |
MNDR | hsa-miR-19a-3p | Duke A | MNDR-E-MI-25384 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022102 |
TOP